Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
M&A momentum is building in the pharma space, with more deals announced last week, including Eli Lilly And Co (NYSE:LLY)'s $8-billion move to acquire Loxo Oncology Inc (NASDAQ:LOXO).
The following catalysts could impact sentiment toward biotech stocks in the unfolding week.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Conferences
- 2019 ASCO Gastrointestinal Cancers Symposium: Jan.17-19 in San Francisco, California.
- 21st Annual Needham Growth Conference: Jan. 15-16 in New York City.
PDUFA Dates
Exelixis, Inc. (NASDAQ:EXEL) awaits the FDA's verdict on its sNDA for cabozantinib, which is being evaluated for patients with previously treated advanced hepatocellular carcinoma. The D-day is Monday.
The FDA is set to rule Friday on Immunomedics, Inc. (NASDAQ:IMMU)'s BLA for sactuzumab govitecan, its investigational candidate for metastatic triple-negative breast cancer in patients who have previously received at least two prior therapies.
Adcom Meetings
The Bone, Reproductive and Urologic Drugs Advisory Committee is scheduled for a discussion Wednesday about Amgen, Inc. (NASDAQ:AMGN)'s BLA for romosozumab injections for osteoporosis in postmenopausal women at high risk of fracture.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
The Endocrinologic and Metabolic Drugs Advisory Committee will discuss Thursday the NDA for sotagliflozin oral tablets, codeveloped by Sanofi and Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX). The candidate is being evaluated as an adjunct to insulin therapy to improve glycemic control in adults with Type 1 diabetes mellitus.
Clinical Trial Results
ASCO-GI Presentations
Rexahn Pharmaceuticals, Inc. (NYSE:RNN) will present updated Phase 2 data for its RX-3117, in combination with Abraxane, which is being evaluated as a first-line treatment for pancreatic cancer.
TRACON Pharmaceuticals Inc (NASDAQ:TCON) is due to present full Phase 2 data for TRC105 and Nexavar in hepatocellular carcinoma.
ASLAN PHARMACEU/ADR (NASDAQ:ASLN) is expected to present new Phase 1/2 data for its Varlitinib plus gemcitabine and cisplatin in biliary tract cancer.
Tyme Technologies Inc (NASDAQ:TYME) will present interim Phase 2 data for its pancreatic cancer treatment candidate SM-88.
Five Prime Therapeutics Inc (NASDAQ:FPRX) and Zai Lab Ltd (NASDAQ:ZLAB) are due to present Phase 1 data for their gastric and gastro-esophageal junction cancer treatment candidate FPA144 along with chemotherapy.
Related Links:
5 Top-Selling Drugs With Growth Potential In 2019
Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.